SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending after reporting strong earnings and significantly raising its future revenue guidance, fueled by accelerating AI cloud growth and massive, pre-funded customer demand for its infrastructure. The community is intensely debating a potential short squeeze and sustained rally, with many anticipating significant upgrades, while some speculate about a profit-taking sell-off at market open.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is surging after reporting its first-ever quarterly net profit and robust delivery guidance, fueling community excitement that its multi-brand strategy and advanced in-house AI chip development are positioning it as more than just an EV maker, with many anticipating a significant short squeeze.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

Investors are keenly awaiting TSSI's unexpectedly early earnings report, driving high community expectations for a significant rebound, especially given its integral role in Dell's expanding AI infrastructure following previous challenging quarters.

goeasy Ltd. engages in the provision of non-prime leasing and lending services. The company was founded by Gordon J. Reykdal on December 14, 1990 and is headquartered in Mississauga, Canada.

Goeasy Ltd

Goeasy Ltd. is trending due to the immediate suspension of its dividend and withdrawal of financial outlook, coupled with revelations of mismanagement, particularly regarding surging loan losses in its auto and powersports divisions. The community is actively discussing management's credibility, especially after a prior short report, with debates between calls for selling amidst bankruptcy fears and some investors eyeing a deep value buying opportunity.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is drawing significant attention after its consolidated deep-seabed mining application was deemed in substantial compliance by NOAA, marking a key regulatory milestone for the expanded project. The community is buzzing with optimism, anticipating further de-risking and discussing the geopolitical importance of securing critical minerals amidst global supply chain concerns.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics (PLYX), a recently direct-listed clinical-stage biotech, is experiencing extreme volatility and massive trading volume following news of its planned Phase 2 trial for lead candidate PLX-200 for rare diseases. The community is buzzing with short squeeze speculation driven by a low float and high cost to borrow, despite concerns about potential dilution after dramatic price swings.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis AG

Novartis is a key topic amid a flurry of positive clinical developments and strategic M&A, highlighted by recent trial success for drugs like remibrutinib and vanrafia, and significant acquisitions including Avidity Biosciences. These advancements are boosting sales forecasts and positioning the company as a leader in next-generation therapies, drawing strong community interest.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending after regaining NASDAQ compliance and reporting strong preliminary financial estimates, reinforcing a turnaround narrative, with the community actively debating its significant undervaluation and potential for a short squeeze.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is intensely trending as the community eagerly awaits pivotal Phase 3 REGAL trial results for its GPS drug in AML, with bullish investors anticipating a groundbreaking, potentially curative outcome and a major acquisition, while skeptics raise concerns about trial design and the company's valuation.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The iShares Biotechnology ETF is experiencing significant trending interest due to a surge in M&A activity, with big pharma acquiring companies at substantial premiums, fostering community discussions around a new bullish phase for the sector driven by both these buyouts and the accelerating impact of AI on drug discovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) Director Kevin Tang purchased 516,439 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, February 27th. The...

GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH

GSA Capital Partners LLP trimmed its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) by 95.9% in the 3rd quarter, according to its most recent 13F filing with the...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.53 earnings per share (EPS) for the quarter...

Aurinia Pharmaceuticals Q4 Earnings Call Highlights

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported fourth-quarter and full-year 2025 results on its latest earnings call, highlighting continued growth from its lupus nephritis therapy LUPKYNIS and...

Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +25.79% and +3.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.</li><li>LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.</li><li>Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.</li></ul>Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Active Lupus Nephritis Therapy Sales Gain Momentum</h2>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user called Aurinia’s earnings and cash position “solid.”<stembedurl>https://stocktwits.com/VSTN/message/645950955</stembedurl>Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.<stembedurl>https://stocktwits.com/Ballerdad1/message/645950749</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down 10% year-to-date, but up 80% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/celh-stock-soaring-today-celsius-q4-earnings-beat/cZTG9gDRIb8">CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Equity

Earnings Summary: Aurinia Pharmaceuticals Q4

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial...

Earnings Preview: Aurinia Pharmaceuticals

United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of +13.50% and -1.88%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc